Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...
Q2 EPS Forecast for Bristol-Myers Squibb Lifted by Analyst
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a four-day winning streak.
Why Is BMY Stock Falling Behind?
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
Medical Dialogues1h
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
Analysts Offer Insights on Healthcare Companies: Ascend Wellness Holdings LLC (OtherAAWH), Bristol-Myers Squibb (BMY) and Caribou Biosciences (CRBU)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...
Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now
We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...
Bristol Myers says over 50% responded to Sotyktu in psoriatic arthritis trial
Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...
Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash
Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...
With 78% institutional ownership, Bloomsbury Publishing Plc (LON:BMY) is a favorite amongst the big guns
Every investor in Bloomsbury Publishing Plc (LON:BMY) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 78% ownership. Put ...